H11-Alb-hHSD17B13(2) Mouse
製品名
H11-Alb-hHSD17B13(2) Mouse
製品ID
C002122
系統名
C57BL/6Cya-Igs2em2(Alb-hHSD17B13)/Cya
背景情報
C57BL/6Cya
状況
このマウス系統を論文で使用する場合は、「H11-Alb-hHSD17B13(2) Mouse（カタログ番号C002122）はサイアジェンから購入しました。」と引用してください。
製品タイプ
年齢
遺伝子型
性別
数量
遺伝子名
遺伝子別名
FLDP, SCDR9, NIIL497, SDR16C3, HMFN0376
NCBI ID
染色体
Chr 4
MGI ID
さらに
系統詳細
17β-hydroxysteroid dehydrogenase 13 (HSD17B13) is a liver-enriched lipid droplet (LD)-associated protein that catalyzes the interconversion between 17-ketosteroids and 17-hydroxysteroids. HSD17B13 protein is selectively expressed in liver cells and localizes exclusively to the surface of lipid droplets, with similar tissue distribution and subcellular localization observed in both humans and mice [1]. HSD17B13 may play a significant role in regulating the biogenesis, growth, and degradation of lipid droplets in the liver. Metabolic-associated fatty liver disease (MAFLD) is pathologically defined by abnormal accumulation of neutral lipids (such as triglycerides and cholesterol esters) within hepatocellular lipid droplets. Its inflammatory form, metabolic-associated steatohepatitis (MASH), is closely associated with the pathogenesis of chronic liver diseases. Research has found that HSD17B13 protein expression is markedly elevated in the livers of MAFLD patients compared to healthy individuals [2-3]. Abnormal expression and dysfunction of HSD17B13 may be one of the pathogenic mechanisms of chronic liver disease, particularly in the MAFLD. As a potential therapeutic target for MAFLD and MASH, there are currently clinical-stage drug pipelines targeting the HSD17B13 gene, including siRNA drug Rapirosiran developed by Regeneron Pharmaceuticals.
The H11-Alb-hHSD17B13(2) mouse model is generated by integrating the "Alb promoter-5'UTR of Human HSD17B13-Human HSD17B13 CDS-3'UTR of Human HSD17B13-WPRE-BGH pA" cassette into the mouse H11 safe harbor locus. This model can be used to study the pathogenic mechanisms of the HSD17B13 gene in metabolic-associated fatty liver disease (MAFLD) and related chronic liver diseases, as well as for evaluating targeted drug development.
参考文献
Zhang HB, Su W, Xu H, Zhang XY, Guan YF. HSD17B13: A Potential Therapeutic Target for NAFLD. Front Mol Biosci. 2022 Jan 7;8:824776.
Su W, Wang Y, Jia X, Wu W, Li L, Tian X, Li S, Wang C, Xu H, Cao J, Han Q, Xu S, Chen Y, Zhong Y, Zhang X, Liu P, Gustafsson JÅ, Guan Y. Comparative proteomic study reveals 17β-HSD13 as a pathogenic protein in nonalcoholic fatty liver disease. Proc Natl Acad Sci U S A. 2014 Aug 5;111(31):11437-42.
Ma Y, Belyaeva OV, Brown PM, Fujita K, Valles K, Karki S, de Boer YS, Koh C, Chen Y, Du X, Handelman SK, Chen V, Speliotes EK, Nestlerode C, Thomas E, Kleiner DE, Zmuda JM, Sanyal AJ; (for the Nonalcoholic Steatohepatitis Clinical Research Network); Kedishvili NY, Liang TJ, Rotman Y. 17-Beta Hydroxysteroid Dehydrogenase 13 Is a Hepatic Retinol Dehydrogenase Associated With Histological Features of Nonalcoholic Fatty Liver Disease. Hepatology. 2019 Apr;69(4):1504-1519.
系統作製戦略
The "Alb promoter-5'UTR of Human HSD17B13-Human HSD17B13 CDS-3'UTR of Human HSD17B13-WPRE-BGH pA" cassette was inserted into H11 locus.
Figure 1. Gene editing strategy for H11-Alb-hHSD17B13(2) mice.
適用分野
Research on chronic liver diseases such as metabolic-associated fatty liver disease (MAFLD) and metabolic-associated steatohepatitis (MASH);
Research, screening, and preclinical evaluation of HSD17B13-targeted drugs.
お問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。